Skip to content
Biotechnology

BTC announces CFO and Company Secretary appointment

BTC Health Limited (ASX:BTC) 2 mins read

Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce the appointment of Salesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025. This appointment reflects the underlying expansion of the BTC business, and the appointment of Josh Kahanovitz, current Head of Finance, into the role of Chief Operating Officer from 17 March 2025.

Salesh joins BTC from Universal Biosensors Australia, where he was the Chief Financial Officer and Company Secretary for more than 18 years. He is a member of the Institute of Chartered Accountants, (CA) and Certified Practicing Accountants (CPA).

BTC’s current Company Secretary, Tracy Weimar, will remain in place through 16 March 2025 and resign to coincide with Salesh's appointment. For the purposes of ASX Listing Rule 12.6, Salesh will be responsible for communications between the Company and ASX from 17 March 2025.

BTC Health Executive Chairman Dr Richard Treagus said, “I am delighted to welcome Salesh to BTC. He brings significant international experience applicable to high-growth companies in the healthcare and medical sectors. He joins us at an exciting time in BTC’s growth journey and he will be a valuable addition to the leadership team.


About us:

About BTC Health
BTC Health is a registered Pooled Development Fund and has investments in three core medical companies:

- BTC Speciality Health, which is responsible for the commercialisation and distribution of medical devices and medical consumables in the therapeutic categories of acute pain management and neurospinal surgery.
- BTC Pharma, which undertakes the registration, development, sales and marketing of specialised pharmaceutical medicines, that serve niche markets and rare diseases.
- BTC Cardio, which is dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products used by cardiac surgeons and critical care experts.


Contact details:

For more information, please contact:

BTC Health Limited (ASX:BTC)
Dr Richard Treagus 
Executive Director
T:  +61 417 520 509 
E: rtreagus@btchealth.com.au

Tracy Weimar
Company Secretary
T: +61 3 9692 7222
E: tracy.weimar@vistra.com

Investor Relations
The Capital Network 
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

More from this category

  • Biotechnology, Business Company News
  • 12/03/2025
  • 09:55
Jane Morgan Management

BlinkLab Commences U.S. Autism Diagnostic Study with First Child Tested

Sydney, Australia – 12 March 2025 | BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) is pleased to announce that the first patient has been tested in its pivotal U.S. autism diagnostic study, marking the official commencement of the largest digital diagnostic trial for autism in the United States. The trial is designed to validate BlinkLab Dx1, an AI-powered, smartphone-based diagnostic tool that aims to become a critical aid for the early assessment of autism. Highlights First U.S. clinical trial participant successfully tested at PriMED Clinical Research LLC in Dayton, Ohio. The study aims to enroll 100 participants at first, expanding…

  • Contains:
  • Biotechnology, Business Company News
  • 11/03/2025
  • 14:19
Jane Morgan Management

ReNerve (ASX:RNV) Expands in Asian Market with NervAlign® Nerve Cuff(TM) Approval in Thailand and First Sales in Hong Kong

11 March 2025 – Sydney, Australia | ReNerve Limited (ASX:RNV) ("ReNerve" or "the Company") is pleased to announce key milestones in its Asian market expansion, including marketing approval for the NervAlign® Nerve Cuff™ in Thailand, as well as its first hospital stocking order in Hong Kong. These developments strengthen ReNerve’s commercial presence outside the initial market it has entered in the United States, and supports its global growth strategy in solutions for peripheral nerve injury, repair, and regeneration. Highlights NervAlign® Nerve Cuff approved for sale in Thailand, paving the way for commercial rollout in the nation of 70+ million people.…

  • Contains:
  • Biotechnology
  • 04/03/2025
  • 22:41
Northway Biotech

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / ACCESS Newswire / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.